Spots Global Cancer Trial Database for asct
Every month we try and update this database with for asct cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | NCT00499018 | Diffuse Large B... IPI≥2 | Rituximab Ciclofosfamide Doxorubicina Vincristina Prednisone Pegfilgrastim Mitoxantrone ARA-C Lenograstim BCNU ARA-C VP-16 ASCT Ciclofosfamide Doxorubicina Vincristina | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | NCT00689169 | Lymphoma, Large... | ZBEAM (Zevalin,... ASCT Rituximab | 18 Years - 65 Years | Lymphoma Study Association | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia | NCT02844361 | Waldenström Mac... | autologous stem... conventional ch... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | NCT04760405 | Multiple Myelom... Stem Cell Trans... | Tai Chi Easy | 18 Years - | University of Arizona | |
| High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma | NCT00965289 | B-Cell Lymphoma | Rituximab | 18 Years - 60 Years | Nantes University Hospital | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| Chemotherapy and G-CSF for Mobilization | NCT03442673 | Multiple Myelom... | Vinorelbine Gemcitabine G-CSF | 18 Years - | Insel Gruppe AG, University Hospital Bern | |
| Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | NCT00556127 | Diffuse Large B... POOR PROGNOSIS | Rituximab Epirubicin Cyclophosphamid... Vincristine Prednisone Granulocyte-col... Mitoxantrone Cytarabine ARA-... Dexamethasone Carmustine BCNU Etoposide Melphalan Radiotherapy PBSC reinfusion | 18 Years - 60 Years | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | |
| Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation | NCT03508765 | Multiple Myelom... | Structural Imag... Functional Imag... Digit Span subt... Brief Test of A... Trail Making Te... Auditory Conson... Controlled Oral... Hopkins Verbal ... The Center for ... The Functional ... Blood draw | 60 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma | NCT04760405 | Multiple Myelom... Stem Cell Trans... | Tai Chi Easy | 18 Years - | University of Arizona | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Bortezomib Consolidation Trial | NCT01517724 | Multiple Myelom... | Bortezomib | 18 Years - 70 Years | University College, London | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Bendamustine and Melphalan in Myeloma | NCT03187223 | Multiple Myelom... | Melphalan Bendamustine | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma | NCT00965289 | B-Cell Lymphoma | Rituximab | 18 Years - 60 Years | Nantes University Hospital | |
| Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL | NCT00588094 | Lymphoma B-cell Non-Hodg... | Rituximab, Ifos... | 18 Years - 72 Years | Memorial Sloan Kettering Cancer Center | |
| Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia | NCT02844361 | Waldenström Mac... | autologous stem... conventional ch... | 18 Years - 70 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation | NCT03508765 | Multiple Myelom... | Structural Imag... Functional Imag... Digit Span subt... Brief Test of A... Trail Making Te... Auditory Conson... Controlled Oral... Hopkins Verbal ... The Center for ... The Functional ... Blood draw | 60 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | NCT01852799 | Multiple Myelom... | PAD Followed by... | 18 Years - 65 Years | Shanghai Changzheng Hospital | |
| Bortezomib Consolidation Trial | NCT01517724 | Multiple Myelom... | Bortezomib | 18 Years - 70 Years | University College, London | |
| Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients | NCT02354313 | MANTLE CELL LYM... | Lenalidomide | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | NCT01927718 | Myeloma | Thalidomide Lenalidomide Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL) | NCT01926665 | Lymphoma | Carfilzomib Dexamethasone | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Rituximab Maintenance After Autologous Transplantation | NCT01103388 | Non-Hodgkin's L... | Rituximab | - | M.D. Anderson Cancer Center | |
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | NCT00916058 | Multiple Myelom... | Bendamustine Melphalan Bendamustine Bendamustine Bendamustine Bendamustine Bendamustine | 18 Years - | Weill Medical College of Cornell University | |
| Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | NCT02655458 | Multiple Myelom... | Elotuzumab Lenalidomide autologous PBMC... ASCT | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | NCT06377540 | Autologous Stem... Classic Hodgkin... | Pembrolizumab Autologous stem... Carmustine Etoposide Cytarabine Melphalan | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | NCT06140966 | Multiple Myelom... Primary Plasma ... Extramedullary ... | Daratumumab Carfilzomib Lenalidomide Dexamethasone Cisplatin epirubicin Cyclophosphamid... Etoposide Melphalan ASCT bortezomib | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Bendamustine and Melphalan in Myeloma | NCT03187223 | Multiple Myelom... | Melphalan Bendamustine | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas | NCT03187210 | Lymphoma | Brentuximab Ved... BeEAM Regimen | 18 Years - 75 Years | Insel Gruppe AG, University Hospital Bern | |
| MInimal Residual Disease Adapted Strategy | NCT04934475 | Multiple Myelom... | Isatuximab ASCT | 18 Years - 66 Years | Intergroupe Francophone du Myelome | |
| A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | NCT01868828 | Multiple Myelom... | PAD VCD ASCT | - 65 Years | Peking University People's Hospital | |
| Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | NCT00651937 | Multiple Myelom... Primary Amyloid... | Melphalan Stem Cell Infus... Questionnaires Granulocyte-col... Apheresis | 60 Years - | M.D. Anderson Cancer Center | |
| Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | NCT00916058 | Multiple Myelom... | Bendamustine Melphalan Bendamustine Bendamustine Bendamustine Bendamustine Bendamustine | 18 Years - | Weill Medical College of Cornell University | |
| Non-interventional Study on Salvage Auto in Relapsed Myeloma | NCT02439476 | Relapsed Multip... | 18 Years - 75 Years | Association for Training, Education, and Research in Hematology, Immunology, and Transplantation | ||
| Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | NCT05239676 | Lymphoma | Autologous hema... | 18 Years - | Zhejiang University | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | NCT01852799 | Multiple Myelom... | PAD Followed by... | 18 Years - 65 Years | Shanghai Changzheng Hospital | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | NCT00695409 | Lymphoma | rituximab carmustine cytarabine etoposide melphalan ASCT yttrium Y 90 ib... | 18 Years - | City of Hope Medical Center | |
| Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients | NCT02354313 | MANTLE CELL LYM... | Lenalidomide | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT | NCT01286675 | Multiple Myelom... | Eltrombopag | 18 Years - 70 Years | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
